CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues
Revenues	$ 8,124	$ 8,434	$ 8,027
Expenses
Selling, general and administrative	2,625	2,624	2,367
Research and development	529	465	452
Amortization of intangible assets	1,215	1,375	1,645
Goodwill impairments	824	469	0
Asset impairments, including loss on assets held for sale	15	234	114
Restructuring, integration, separation and IPO costs	63	50	22
Other expense, net	35	373	502
Total Expenses	7,670	7,984	7,351
Operating income	454	450	676
Interest income	14	7	13
Interest expense	(1,464)	(1,426)	(1,534)
Gain (loss) on extinguishment of debt	875	(62)	(59)
Foreign exchange and other	(8)	7	(30)
Loss before income taxes	(129)	(1,024)	(934)
(Provision for) benefit from income taxes	(83)	87	375
Net loss	(212)	(937)	(559)
Net income attributable to noncontrolling interest	(13)	(11)	(1)
Net loss attributable to Bausch Health Companies Inc.	$ (225)	$ (948)	$ (560)
Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)	$ (0.62)	$ (2.64)	$ (1.58)
Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)	$ (0.62)	$ (2.64)	$ (1.58)
Basic weighted-average common shares (in shares)	362,000	358,900	355,000
Diluted weighted-average common shares (in shares)	362,000	358,900	355,000
Product sales
Revenues
Revenues	$ 8,046	$ 8,342	$ 7,924
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	2,336	2,361	2,202
Other revenues
Revenues
Revenues	78	92	103
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	$ 28	$ 33	$ 47